Early detection saves lives—but access must reach everyone.
In conjunction with World Cancer Day 2026, Gene Solutions Malaysia and the National Cancer Society Malaysia (NCSM) officially signed a Memorandum of Understanding (MOU), marking the soft launch of the Early4Life Campaign.
This partnership represents a shared commitment to expanding cancer awareness and improving access to early detection nationwide.
As part of this initiative, SPOT-MAS 10, an AI-powered, Multi-Cancer Early Detection (MCED) blood test, will be provided to support B40 communities through NCSM outreach programs starting this year. Designed for healthy individuals aged 40 and above, this non-invasive liquid biopsy requires only a 10 mL blood sample to screen for early cancer signals and help predict potential tumor locations.
This MOU is just the beginning. Stay tuned as we continue to roll out the Early4Life Campaign.
About Gene Solutions Malaysia
Established in 2023, Gene Solutions Malaysia is part of Gene Solutions, a global biotechnology company headquartered in Singapore and dedicated to making advanced genomic solutions more accessible and affordable.
We provide genomic testing and precision healthcare solutions across oncology, reproductive health and women’s health, leveraging Next-Generation Sequencing (NGS), multi-omics and Artificial Intelligence (AI).
The company offers a comprehensive portfolio across oncology, including early cancer screening (SPOT-MAS CRC, SPOT-MAS Lung), multi-cancer early detection (SPOT-MAS 10), and precision oncology (K-TRACK, K4CARE), as well as reproductive and women’s health solutions, including non-invasive prenatal testing (TriSure) and gynecologic cancer screening and triage (SPOT-MAS Eva, EpiHera).
Through collaborations with hospitals, healthcare institutions, laboratories and medical professionals across Malaysia, we are working to bring innovative genomic solutions into clinical practice and contribute to the advancement of precision medicine.
